HC Wainwright Issues Pessimistic Estimate for CKPT Earnings

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) – HC Wainwright reduced their FY2024 earnings estimates for Checkpoint Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.94) per share for the year, down from their previous forecast of ($0.80). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Checkpoint Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Checkpoint Therapeutics’ Q4 2024 earnings at ($0.22) EPS.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08).

Checkpoint Therapeutics Price Performance

NASDAQ CKPT opened at $3.38 on Monday. The business has a fifty day moving average price of $2.87 and a two-hundred day moving average price of $2.38. The stock has a market capitalization of $152.17 million, a PE ratio of -1.84 and a beta of 1.23. Checkpoint Therapeutics has a fifty-two week low of $1.36 and a fifty-two week high of $3.97.

Institutional Trading of Checkpoint Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Checkpoint Therapeutics by 67.4% in the first quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock valued at $1,882,000 after acquiring an additional 369,586 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Checkpoint Therapeutics by 41.2% in the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after acquiring an additional 124,787 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in shares of Checkpoint Therapeutics by 366.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after purchasing an additional 180,050 shares in the last quarter. PVG Asset Management Corp bought a new stake in shares of Checkpoint Therapeutics during the 2nd quarter valued at approximately $295,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in Checkpoint Therapeutics by 160.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after purchasing an additional 80,000 shares in the last quarter. 22.00% of the stock is currently owned by institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.